• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

使用吡非尼酮后出现严重光敏反应。

Severe Photosensitivity Reaction After Pirfenidone Use.

作者信息

Choudhury Saiara, Taweesedt Pahnwat T, Dadhwal Rahul, Surani Salim

机构信息

Internal Medicine, Corpus Christi Medical Center, Corpus Christi, USA.

Pulmonary Medicine, Corpus Christi Medical Center, Corpus Christi, USA.

出版信息

Cureus. 2021 Jul 25;13(7):e16626. doi: 10.7759/cureus.16626. eCollection 2021 Jul.

DOI:10.7759/cureus.16626
PMID:34458037
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8384726/
Abstract

Idiopathic pulmonary fibrosis is a chronic and progressive disease with a significant mortality rate. Pirfenidone is one of two oral antifibrotic therapies approved to treat idiopathic pulmonary fibrosis (IPF). Pirfenidone helps decrease disease progression in patients with IPF and reduces vital capacity. This has led to widespread use of this medication in recent years. In this case report, we present a 60-year-old male who started treatment with pirfenidone for IPF and had severe skin reactions after initiation of therapy.

摘要

特发性肺纤维化是一种慢性进行性疾病，死亡率较高。吡非尼酮是被批准用于治疗特发性肺纤维化（IPF）的两种口服抗纤维化疗法之一。吡非尼酮有助于减缓IPF患者的疾病进展，并降低肺活量。这使得该药物近年来得到广泛应用。在本病例报告中，我们介绍了一名60岁男性，他开始使用吡非尼酮治疗IPF，治疗开始后出现了严重的皮肤反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f98a/8384726/2291ef6b888f/cureus-0013-00000016626-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f98a/8384726/fe3fa95e7739/cureus-0013-00000016626-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f98a/8384726/2291ef6b888f/cureus-0013-00000016626-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f98a/8384726/fe3fa95e7739/cureus-0013-00000016626-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f98a/8384726/2291ef6b888f/cureus-0013-00000016626-i02.jpg

相似文献

1
Severe Photosensitivity Reaction After Pirfenidone Use.使用吡非尼酮后出现严重光敏反应。
Cureus. 2021 Jul 25;13(7):e16626. doi: 10.7759/cureus.16626. eCollection 2021 Jul.
2
Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena.吡非尼酮治疗特发性肺纤维化：锡耶纳转诊中心的真实临床经验。
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620906326. doi: 10.1177/1753466620906326.
3
Pirfenidone-induced severe phototoxic reaction in a patient with idiopathic lung fibrosis.吡非尼酮诱发特发性肺纤维化患者发生严重光毒性反应。
J Eur Acad Dermatol Venereol. 2016 Aug;30(8):1354-6. doi: 10.1111/jdv.13657. Epub 2016 Mar 23.
4
Role of pirfenidone in the management of pulmonary fibrosis.吡非尼酮在肺纤维化管理中的作用。
Ther Clin Risk Manag. 2017 Apr 3;13:427-437. doi: 10.2147/TCRM.S81141. eCollection 2017.
5
Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone.接受吡非尼酮治疗的特发性肺纤维化患者的抗酸治疗与疾病进展
Respiration. 2017;93(6):415-423. doi: 10.1159/000468546. Epub 2017 Apr 12.
6
All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis.对1371例接受吡非尼酮治疗特发性肺纤维化患者的全病例上市后监测。
Respir Investig. 2015 Sep;53(5):232-41. doi: 10.1016/j.resinv.2015.06.001. Epub 2015 Aug 17.
7
Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.乙酰半胱氨酸和吡非尼酮联合治疗特发性肺纤维化的安全性和耐受性：一项随机、双盲、安慰剂对照、2 期临床试验。
Lancet Respir Med. 2016 Jun;4(6):445-53. doi: 10.1016/S2213-2600(16)30044-3. Epub 2016 May 5.
8
Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients.特发性肺纤维化患者起始抗纤维化治疗后，18F-FDG PET/CT 评估早期代谢无应答。
Respir Res. 2019 Jan 15;20(1):10. doi: 10.1186/s12931-019-0974-5.
9
A multicentre retrospective observational study on Polish experience of pirfenidone therapy in patients with idiopathic pulmonary fibrosis: the PolExPIR study.波兰特发性肺纤维化患者吡非尼酮治疗的多中心回顾性观察研究：PolExPIR 研究。
BMC Pulm Med. 2020 May 4;20(1):122. doi: 10.1186/s12890-020-1162-6.
10
Pirfenidone: a review of its use in idiopathic pulmonary fibrosis.吡非尼酮：在特发性肺纤维化中的应用评价。
Drugs. 2015 Feb;75(2):219-30. doi: 10.1007/s40265-015-0350-9.

本文引用的文献

1
Pirfenidone-Induced Photosensitive Dermatitis: A Rare Side Effect.吡非尼酮诱导的光敏性皮炎：一种罕见的副作用。
Cureus. 2021 May 23;13(5):e15200. doi: 10.7759/cureus.15200.
2
Pirfenidone-induced photosensitivity confirmed by pathological phototest.吡非尼酮诱导的光敏感性通过病理光试验得到证实。
Photodiagnosis Photodyn Ther. 2019 Mar;25:103-105. doi: 10.1016/j.pdpdt.2018.11.015. Epub 2018 Nov 20.
3
Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis.吡非尼酮治疗特发性肺纤维化的安全性和不良反应事件管理。
Eur Respir Rev. 2017 Dec 6;26(146). doi: 10.1183/16000617.0057-2017. Print 2017 Dec 31.
4
Overview of idiopathic pulmonary fibrosis (IPF) and evidence-based guidelines.特发性肺纤维化（IPF）概述和循证指南。
Am J Manag Care. 2017 Jul;23(11 Suppl):S176-S182.
5
Efficacy and adverse events of pirfenidone in treating idiopathic pulmonary fibrosis.吡非尼酮治疗特发性肺纤维化的疗效及不良事件
Saudi Med J. 2017 Sep;38(9):889-894. doi: 10.15537/smj.2017.9.19349.
6
Pirfenidone in the treatment of idiopathic pulmonary fibrosis: an evidence-based review of its place in therapy.吡非尼酮治疗特发性肺纤维化：对其在治疗中地位的循证综述
Core Evid. 2016 Jul 1;11:11-22. doi: 10.2147/CE.S76549. eCollection 2016.
7
Photosafety assessments on pirfenidone: photochemical, photobiological, and pharmacokinetic characterization.吡非尼酮的光安全性评估：光化学、光生物学和药代动力学特征。
J Photochem Photobiol B. 2013 Mar 5;120:44-51. doi: 10.1016/j.jphotobiol.2013.01.010. Epub 2013 Jan 29.
8
Pirfenidone: a novel agent for the treatment of idiopathic pulmonary fibrosis.吡非尼酮：一种治疗特发性肺纤维化的新型药物。
Ann Pharmacother. 2013 Mar;47(3):361-7. doi: 10.1345/aph.1R337. Epub 2013 Feb 12.